Martin Tami Tillotson 4/A
4/A · SUPERNUS PHARMACEUTICALS, INC. · Filed Apr 12, 2023
Insider Transaction Report
Form 4/AAmended
Martin Tami Tillotson
VP of Regulatory Affairs
Transactions
- Tax Payment
Common Stock
2023-02-22$38.57/sh−289$11,147→ 90,034 total - Disposition to Issuer
Restricted Stock Units
2023-02-22−750→ 2,250 total→ Common Stock (750 underlying) - Award
Common Stock
2023-02-22+750→ 90,323 total
Footnotes (4)
- [F1]Includes an aggregate of 853 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
- [F2]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
- [F3]Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- [F4]These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023.